Free Trial
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

Genmab A/S logo
$20.41 -0.03 (-0.15%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$20.41 0.00 (0.00%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Genmab A/S Stock (NASDAQ:GMAB)

Key Stats

Today's Range
$20.23
$20.44
50-Day Range
$19.08
$23.09
52-Week Range
$17.24
$28.56
Volume
1.13 million shs
Average Volume
1.23 million shs
Market Capitalization
$13.09 billion
P/E Ratio
11.60
Dividend Yield
N/A
Price Target
$37.60
Consensus Rating
Moderate Buy

Company Overview

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

GMAB MarketRank™: 

Genmab A/S scored higher than 72% of companies evaluated by MarketBeat, and ranked 865th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Genmab A/S has only been the subject of 1 research reports in the past 90 days.

  • Read more about Genmab A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Genmab A/S are expected to grow by 22.76% in the coming year, from $1.45 to $1.78 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 11.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.58.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 11.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Earnings Growth Ratio

    Genmab A/S has a PEG Ratio of 6.74. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Genmab A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.36% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.36% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Genmab A/S this week, compared to 7 articles on an average week.
  • Search Interest

    Only 3 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genmab A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.54% of the stock of Genmab A/S is held by insiders.

  • Percentage Held by Institutions

    Only 7.07% of the stock of Genmab A/S is held by institutions.

  • Read more about Genmab A/S's insider trading history.
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Stock News Headlines

Genmab Announces Changes to its Executive Committee
Completion of Share Buy-back Program
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Transactions in Connection with Share Buy-back Program
See More Headlines

GMAB Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $20.87 on January 1st, 2025. Since then, GMAB shares have decreased by 2.2% and is now trading at $20.41.

Genmab A/S Sponsored ADR (NASDAQ:GMAB) announced its quarterly earnings results on Thursday, May, 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The company had revenue of $715 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a trailing twelve-month return on equity of 18.08%.
Read the conference call transcript
.

Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Genmab A/S's top institutional shareholders include Marotta Asset Management.

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
2,682
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$37.60
High Stock Price Target
$48.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+84.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
11.60
Forward P/E Ratio
14.08
P/E Growth
6.74
Net Income
$1.14 billion
Pretax Margin
40.96%

Debt

Sales & Book Value

Annual Sales
$3.12 billion
Cash Flow
$1.51 per share
Price / Cash Flow
13.48
Book Value
$8.04 per share
Price / Book
2.54

Miscellaneous

Free Float
631,346,000
Market Cap
$13.09 billion
Optionable
Optionable
Beta
0.94

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:GMAB) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners